IDEXX Laboratories today announced the mid-2026 expansion of its Cancer Dx™ Panel to include detection of canine mast cell tumors, representing over one-third of all canine cancer cases. More than 5,500 practices across the U.S. and Canada currently use the lymphoma test, which identifies disease up to eight months before clinical signs emerge, and mast cell tumor detection will be added at no extra cost. Results will be delivered within 2–3 days in the U.S. (2–4 days in Canada) using the same specimen requirements and workflow. This enhancement enables veterinarians to screen at-risk dogs—defined as all dogs seven years or older and high-risk breeds four years or older—during routine wellness visits and to test symptomatic patients promptly. The panel’s high sensitivity and specificity support earlier treatment decisions and improved patient outcomes.

In late Q4 2025, IDEXX began a controlled rollout of FNA cytology on its inVue Dx™ Cellular Analyzer, featuring a slide-free design and expert review option without slide preparation. Initially focused on mast cell tumor detection for dogs, this application delivers same-visit insights into skin mass cellularity, enabling veterinarians to identify and quantify suspicious cells while pet owners remain in the clinic. Over time, the FNA cytology menu will expand beyond mast cell tumors. By reducing the time between sample collection and diagnostic guidance—and offering optional remote pathologist review—IDEXX inVue Dx addresses a critical bottleneck in veterinary oncology and empowers practitioners to initiate timely, targeted treatments.

IDEXX launched the ImageVue™ DR50 Plus Digital Imaging System, offering up to 25% lower radiation dose than its predecessor and up to 60% lower dose compared with competing veterinary systems. The platform integrates AI-powered image optimization, automated exposure protocols and irradiated side sampling to reduce retakes and enhance image clarity. A new 17" x 17" panel option expands coverage for larger patients, while seamless integration with IDEXX Web PACS™ and ezyVet™ software streamlines image capture, case submission and storage. Veterinarians gain access to 160+ board-certified telemedicine specialists through a 45% reduction in clicks required for case transfer, promoting faster, more confident diagnoses in practices across the United States and Canada.

Headquartered in Westbrook, Maine, IDEXX employs approximately 11,000 people and serves customers in more than 175 countries and territories. A member of the S&P 500 Index, the company’s diagnostic and software offerings support veterinary teams worldwide with innovations that advance pet healthcare, improve operational efficiency and enhance milk and water safety. IDEXX’s ongoing product rollouts and connected workflows reinforce its leadership in pet healthcare diagnostics and position the company for sustained revenue growth through expanded service penetration and technology adoption.